首页> 外文OA文献 >Antifracture drugs consumption in Tuscany Region before the Target Project: a valuable model for the analysis of administrative database
【2h】

Antifracture drugs consumption in Tuscany Region before the Target Project: a valuable model for the analysis of administrative database

机译:目标项目前托斯卡纳地区的抗骨折药物消费:行政数据库分析的一个有价值的模型

摘要

Objectives. As the Target Project of Tuscany Region is aimed to identify significant changes occurring during the time of the project compared to the previous years, we have analyzed antifracture drugs consumption in the years immediately preceding the start-up of the program. Methods. We have analyzed the regional administrative database to search for antifracture drugs delivered by the regional healthcare system to people living in Tuscany in the year 2009. Both drugs directly distributed by hospitals or local health authorities (direct distribution dataset, FED), and those delivered through pharmacies (pharmaceutical distribution dataset, SPF) were included in the analysis. Private expenditures were indirectly computed because total pharmaceutical expenditures were also known. A specific subgroup analysis has been carried out on elderly patients with femoral fractures (years 2006-2010), which represent the population of Target Project, in order to assess the evolution of all antifracture drug prescriptions before the start up of the project. Results. A total of 690,768 boxes of antifracture drugs (20 million defined daily doses, DDD) have been delivered in year 2009 for total expenditures of 23 million Euros. Public expenditures accounted for 71% of the total (16 million; 6% of regional pharmaceutical expenditures). Alendronate and risedronate were the most used drugs. The number of antifracture medications prescribed within the first 90 days to elderly people with hip fractures increased in the period before the start-up of the Target project but they remained under 14%. Conclusions. There is the need for an appropriate management of antifracture therapies, as they represent a valuable proportion of pharmaceutical expenditures. This need is pointed out also by the remarkable amount of direct private expenditures and by the few number of hip fractured people starting a treatment
机译:目标。由于托斯卡纳地区的目标项目旨在确定项目期间与前几年相比发生的重大变化,因此我们分析了该计划启动前几年的抗裂药消费量。方法。我们分析了地区行政数据库,以搜索地区医疗保健系统在2009年向托斯卡纳居民提供的抗骨折药物。医院或地方卫生当局直接分发的药物(直接分发数据集,FED)以及通过分析中包括药房(药品分​​布数据集,SPF)。私人支出是间接计算的,因为医药总支出也是已知的。已对代表目标项目人群的老年股骨骨折患者(2006-2010年)进行了具体的亚组分析,以便在项目启动之前评估所有抗骨折药物处方的发展。结果。 2009年,共交付了690,768箱抗骨折药物(2000万确定的日剂量,DDD),总支出为2300万欧元。公共支出占总支出的71%(1600万;占地区药品支出的6%)。阿仑膦酸盐和利塞膦酸盐是最常用的药物。在Tar​​get项目启动之前的90天内,针对患有髋部骨折的老年人开具的抗骨折药物的数量有所增加,但仍低于14%。结论。有必要对抗骨折治疗进行适当的管理,因为它们占药物支出的重要部分。大量的直接私人支出以及为数不多的开始治疗的髋部骨折患者也指出了这一需求。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号